IMUX vs. ABEO, RZLT, CLRB, ADAG, FGEN, CRVS, CTXR, PMVP, COYA, and RLMD
Should you be buying Immunic stock or one of its competitors? The main competitors of Immunic include Abeona Therapeutics (ABEO), Rezolute (RZLT), Cellectar Biosciences (CLRB), Adagene (ADAG), FibroGen (FGEN), Corvus Pharmaceuticals (CRVS), Citius Pharmaceuticals (CTXR), PMV Pharmaceuticals (PMVP), Coya Therapeutics (COYA), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical preparations" industry.
Immunic (NASDAQ:IMUX) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.
Abeona Therapeutics received 419 more outperform votes than Immunic when rated by MarketBeat users. Likewise, 70.27% of users gave Abeona Therapeutics an outperform vote while only 65.73% of users gave Immunic an outperform vote.
Immunic has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.
In the previous week, Immunic had 6 more articles in the media than Abeona Therapeutics. MarketBeat recorded 11 mentions for Immunic and 5 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 0.84 beat Immunic's score of 0.61 indicating that Abeona Therapeutics is being referred to more favorably in the news media.
Immunic presently has a consensus target price of $8.50, indicating a potential upside of 564.06%. Abeona Therapeutics has a consensus target price of $36.00, indicating a potential upside of 757.14%. Given Abeona Therapeutics' higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Immunic.
Immunic's return on equity of -161.82% beat Abeona Therapeutics' return on equity.
51.8% of Immunic shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 3.0% of Immunic shares are owned by insiders. Comparatively, 5.3% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Abeona Therapeutics has higher revenue and earnings than Immunic. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.
Summary
Abeona Therapeutics beats Immunic on 9 of the 15 factors compared between the two stocks.
Get Immunic News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
